Liver Resection in Hepatitis B-Related Hepatocellular Carcinoma: Clinical Outcomes and Safety in Overweight and Obese Patients

Haiqing Wang, Jian Yang, Xiaowu Zhang, Lunan Yan, Jiayin Yang*
Department of Liver Surgery, West China Hospital of Sichuan University, Chengdu, China

Abstract

Objective and Background: Although many studies on evaluating the safety of liver resection in obese patients have been conducted, the results remain contradictory. The aim of our study was to investigate the safety of overweight and obese patients undergoing liver resection for hepatitis B-related hepatocellular carcinoma in a large sample.

Methods: In a retrospective cohort with 1543 hepatitis B-related hepatocellular carcinoma patients, the subjects were stratified into four groups according to their body mass index (BMI): obesity (BMI ≥ 28), overweight (BMI: 24.0–27.9), normal weight (BMI: 18.5–23.9) and underweight (BMI < 18.5). The Dindo–Clavien classification system was used for grading complications. Clinical characteristics and operative outcomes were compared among the four groups. Risk factors for postoperative complications were evaluated by multivariate analysis.

Results: According to the category criteria of the Working Group on Obesity in China (WGOCC) criteria, 73 (4.7%) obese, 412 (26.7%) overweight, 982 (63.6%) normal weight and 76 (4.9%) underweight patients were included in our cohort. Overweight and obese patients had more preoperative comorbidities such as hypertension (P < 0.001). Mortality, total complications and complications classified by Clavien system were similar among the four groups except that the underweight patients had fewer total complications. However, postoperative wound complication was more common in overweight and obese patients (6.3% vs 2.5%, P < 0.001, 11.0% vs 2.5%, P = 0.001). Multivariate analysis revealed that BMI was not an independently significant factor for postoperative complications.

Conclusions: Liver resection for obese and overweight patients is safe and BMI itself is not a risk factor for mortality and morbidity.

Introduction

Liver resection remains one of the most common and effective treatments for hepatocellular carcinoma (HCC) and has become a widely accepted therapy method[1]. With the refinement of surgical techniques and perioperative management in liver surgery over the past several decades, outcomes after liver resection have improved substantially in recent years. However, the surgeons are facing with new challenge deriving from the longer and more difficult surgeries for obese and overweight patients[2]. With the prevalence of obesity continuously increasing worldwide, obesity and overweight are an increasing public health problem. In the United States[3], 66.2% of adults were obese or overweight in 2003–2004 year. Although there is a much lower prevalence of obesity and overweight in China than in other parts of the world, the condition has increased dramatically during recent decades[4,5]. Obesity in Chinese adults, according to criteria from the Working Group on Obesity in China (WGOCC) criteria, increased during the period from 1993 to 2009, from 2.9% to 8.7%, and the prevalence of overweight increased from 17.4% to 27.5%[4]. Obesity and overweight are associated with an increasing incidence of a number of conditions, including diabetes mellitus, cardiovascular disease, nonalcoholic fatty liver disease, HCC and others[3,6]. In addition, many studies[7–9] have suggested that obesity may have a negative impact on surgical outcomes due to associated co-morbidities, and many studies have assessed the morbidity and mortality in obese patients but the results still remain controversial. Most such studies[7,10–14] were carried out in western countries and the liver resection was performed in patients with all types of liver diseases. Few studies have focused on Chinese people, in whom the prevalence of obesity and overweight has been lower. Moreover, fewer studies have researched the effect of obesity and overweight in HCC patients, in which about 80% of the cases in China occur in cirrhosis of the liver[15].

The aim of our study was to investigate the safety of overweight and obese patients undergoing liver resection for hepatitis B virus (HBV)-related HCC in a large sample.
Liver Resection in Overweight and Obese Patients

Method

Population and Study Design

Between January 2009 and March 2013, 1543 consecutive HBV-related HCC patients undergoing elective liver resection were included in our study. All subjects were diagnosed with HCC by histology and with HBV infection or a history of HBV infection. Patients underwent surgery only when their Child-Turcotte-Pugh (CTP) score was A. Records for patients’ data indicating demographics, comorbid conditions, laboratory values, intraoperative parameters and postoperative outcomes were collected prospectively in the HCC of West China Hospital of Sichuan University database (HCCWCHSU System). The protocol was approved by the West China Hospital Ethical Committee and written informed consent was obtained from all recipients before inclusion. Based on body mass BMI categories of WGOC[5,16] criteria, the patients were stratified into an underweight group (BMI<18.5), a normal weight group (BMI:18.5–23.9), an overweight group (BMI:24.0–27.9) and an obese group (BMI≥28). The primary outcomes of this study were the mortality and postoperative complications in the four groups. The secondary outcome was the co-morbidities among the four groups.

Perioperative Management

All of the patients were managed by the same surgical team. All patients underwent a thorough history enquiry, physical examination and routine preoperative laboratory measurements. Echo-cardiography, chest radiograph or computed tomography, pulmonary function test and coronary angiography were carried out, if necessary. Routine preoperative imaging examinations to evaluate the tumor included contrast computed tomography or magnetic resonance imaging of the abdomen. Patients undergoing surgery were administered under general anesthesia and were explored through an extended right subcostal incision, intraoperative ultrasonography was performed routinely. Hemiepatic vascular inflow occlusion[17] or the Pringle maneuver[18] were used according to the surgeon’s preference in most patients. Liver parenchymal transection was performed using the hooking ligation technique or an ultrasonic dissector with coagulator[17]. Based on preoperative and intraoperative condition, patients were transferred to the intensive care unit for treatment if necessary.

Definition of the Parameters

The Clavien-Dindo complications classification system[19] was used to grade postoperative complications. Complication grade III-V is defined as severe complication. Liver resection of more than three segments was defined as major resection, and liver resection of fewer than three segments was defined as minor resection[20]. Portal hypertension was defined as esophageal varices detected by endoscopy or splenomegaly (major diameter >12 cm) with a platelet count <100 000/mm² according to the Barcelona Clinic Liver Cancer Group criteria[1]. For individual preexisting disease, we used the Charlson index[21,22] to quantify comorbidities. Extrahepatic procedure included all other operations except for liver resection, such as bowel resection, adrenalectomy, diaphragm resection, biliary tract exploration and adhesion separation due to reoperation. Cardiovascular disease included coronary heart disease, previous coronary revascularization, cerebral arterial occlusive disease, and/or peripheral vascular occlusive disease. Pulmonary disease indicated chronic obstructive pulmonary disease, asthma, chronic bronchitis and tuberculosis. Wound complications included infections, hematoma and wound dehiscence. The definition and grading of severity of liver failure were based on International Study Group of Liver Surgery criteria[23]. Histologic staging of fibrosis was performed using the Ishak fibrosis score[24]. We used 30-day mortality and 90-day mortality to evaluated the perioperative mortality.

Statistical Analysis

Statistical analysis was performed using SPSS Version 17 statistical analysis software and significances was set at P<0.05. Continuous variables were compared among groups by the Student t-test or Mann-Whitney U test when appropriate. The Chi-square test or Fisher’s exact test were used to compare categorical variables. To identify risk factors for complications, only factors associated with complications in the univariate analysis with significant difference entered into a forward stepwise logistic regression analysis.

Result

Patient characteristics

Our cohort consisted of 1543 HBV-related HCC patients, with BMIs ranging from 16.4 kg/m² to 35.0 kg/m², and a mean of 22.9 kg/m². Of the subjects, 73 (4.7%) were obese, 412 (26.7%) were overweight, 982 (63.6%) were normal weight and 76 (4.9%) were underweight according to the categories of WGOC criteria. According to the distribution of BMI, we categorized all the patients into four levels. The patient characteristics of the four groups were displayed in Table 1. The gender distribution, the proportion of Charlon index >3, comorbidity and hypertension were significantly different among the four BMI groups. Overweight patients had higher proportion of male subjects (41.3% vs 38.4%, P = 0.01) than the normal weight group and underweight patients had a lower proportion of male subjects than the normal weight group (55.3% vs 88.8%, P<0.001). Compared to patients with normal weight, overweight patients had a higher incidence of comorbidities (35.2% vs 26.3%, P = 0.001), Charlson index >3 (13.6% vs 7.8%, P = 0.001) and hypertension (24.8% vs 14.7%, P < 0.001). The obese patients also had a higher incidence of comorbidities (38.4% vs 26.3%, P = 0.025) and hypertension (31.5% vs 14.7%, P < 0.001) compared to patients with normal weight.

The difference in comorbidities is mainly reflected in higher incidence of hypertension. No significant differences were found for cardiovascular disease, pulmonary disease and diabetes mellitus. Other preoperative parameters such as age, American Society of Anesthesiologists category (ASA), grade, hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), HBV DNA-positive (more than 2000 U/mL), aspartate aminotransferase (AST), alanine aminotransferase (ALT), hemoglobin, platelets, Ishak score, tumor size, tumor number, rate of antiviral treatment before operation and portal hypertension were not significantly different among the four groups. All the patients with HBV DNA positive got antiviral treatment after hepatectomy, however, only 71.2% (344/483) of them had antiviral treatment before surgery.

Intraoperative data

The four groups experienced similar operative procedures (Table 2). Anatomic resection was performed in 557 (36.1%) patients, including 223 right hemihepatectomies, 119 left hemihepatectomies, 114 left lobectomies, 25 mesohepatectomies and 76 other procedures. Based on intraoperative findings and pathological examination, 1430 (92.7%) patients were with R0 resection, 77 (5.0%) with R1 resection and 36 (2.3%) with R2 resection. The rates of major liver resection (P = 0.902) and...
additional extrahepatic procedures ($P = 0.196$) were not different among the four groups. Moreover, the methods used for liver parenchyma transection (hooking ligation or ultrasonic dissector), anatomic resection rate, packed red blood cells (PRBCs) transfusion, plasma transfusion requiremen and inflow occlusion rate during hepatectomy were also similar in the four groups. Patients with BMI $\geq 28$ seemed to have more blood loss, but there were no significant differences ($P = 0.224$).

Postoperative outcomes

Postoperative complications and mortality are shown in Table 3. The overall morbidity, 30-day mortality and 90-day mortality rates in our cohort were 30.1%, 1.5% and 1.6%, respectively. Neither the 30-day mortality nor the 90-day mortality rate was different among the four groups. For comparison, the Clavien-Dindo complications classification system[19] was used in grading postoperative complications. Compared to normal weight patients, total complications were more common in overweight and obese patient, however, no significant differences were reached. The underweight patients had fewer total complication (15.8% vs 29.3%, $P = 0.012$). With regards to specific complications, postoperative common complications included bile leakage, liver failure, ascites, cardiovascular complication, pulmonary complications, infection complications, bleeding, wound complications and gastrointestinal complications. Differences in these complications among the four groups were not significant except for wound complications. Overweight (6.3% vs 2.5%, $P = 0.001$) and obese patient (11.0% vs 2.5%, $P = 0.001$) had more wound complication than the normal weight patients. In addition, required hospital stay (days) ($P = 0.382$) and ICU stay ($P = 0.132$) were not different among the four groups. The perioperative outcomes between overweight and obese patients were similar.

Prognostic factors for complications by logistic analysis

Univariate analysis showed that BMI grade was significantly correlated with postoperative complications ($P = 0.008$). To assess the clinical significance of BMI, we investigated prognostic factors for total complications by logistic regression. Fourteen significant variables in univariate analysis ($P < 0.05$) were identified and they were BMI, gender, major liver resection, extrahepatic procedures, portal hypertension, PRBCs transfusion, Charlson index $>3$, pulmonary disease, diabetes mellitus, ASA grade $\geq III$, AST, ALT, blood loss and platelets. All of the 14 parameters entered into the regression model and significant variables for total complications included gender, major liver resection, extrahepatic procedures, portal hypertension, PRBCs transfusion, pulmonary disease, ASA

### Table 1. Preoperative Characteristics of Patients who underwent Hepatectomy.

| Clinical characteristics                  | Underweight (BMI $<18.5$) | Normal Weight (BMI:18.5–23.9) | Overweight (BMI:24.0–27.9) | Obesity (BMI $\geq 28$) | P Value |
|------------------------------------------|-----------------------------|-------------------------------|-----------------------------|-------------------------|---------|
| Male (%)                                 | 42 *(55.3%)                 | 819(83.4%)                    | 366 *(88.8%)                | 679(91.8%)              | <0.001  |
| Age (year), median (IQR)                 | 53.5(42–63)                 | 50(41–59)                     | 49(41.25–59)                | 47(40.5–56)             | 0.228   |
| ASA grade $\geq III$ (%)                 | 8(10.5%)                    | 143(14.6%)                    | 64(15.5%)                   | 13(17.8%)               | 0.605   |
| Charlson index $>3$ (%)                  | 10 (13.2%)                  | 77(7.8%)                      | 56 *(13.6%)                 | 8(11.0%)                | 0.007   |
| Comorbidity (%)                          | 17(22.4%)                   | 258(26.3%)                    | 145 *(35.2%)                | 28 *(38.4%)             | 0.001   |
| Hypertension (%)                         | 8(10.5%)                    | 144(14.7%)                    | 102 *(24.8%)                | 23 *(31.5%)             | <0.001  |
| Pulmonary disease (%)                    | 4(5.3%)                     | 30(3.1%)                      | 10(2.4%)                    | 3(4.1%)                 | 0.600   |
| Cardiovascular disease (%)               | 0(0%)                       | 23(2.3%)                      | 15(3.6%)                    | 4(5.5%)                 | 0.056   |
| Diabetes mellitus (%)                    | 3(3.9%)                     | 69(7.0%)                      | 40(9.7%)                    | 5(6.8%)                 | 0.205   |
| HBsAg (%)                                | 64(84.2%)                   | 802(81.7%)                    | 333(80.8%)                  | 51(69.9%)               | 0.082   |
| HBeAg (%)                                | 12(15.8%)                   | 145(14.8%)                    | 76 *(18.4%)                  | 13(17.8%)               | 0.372   |
| HBV DNA $>2000$ U/mL (%)                 | 22(28.9%)                   | 301(70.1%)                    | 101(73.3%)                  | 17(73.9%)               | 0.853   |
| Antiviral treatment before hepatectomy   | 15(68.2%)                   | 211(70.1%)                    | 101(73.3%)                  | 17(73.9%)               | 0.853   |
| AST (ULN) $>ULN$ (%)                     | 29(38.2%)                   | 410(41.8%)                    | 167(40.5%)                  | 30(41.1%)               | 0.921   |
| ALT (ULN) $>ULN$ (%)                     | 17(22.4%)                   | 277(28.2%)                    | 114(27.7%)                  | 25(34.2%)               | 0.450   |
| Hemoglobin(g/l) $>120$ g/L (%)           | 59(77.6%)                   | 838(85.3%)                    | 362(87.9%)                  | 66(90.4%)               | 0.070   |
| Platelets (10$^9$/L, median (IQR))       | 146(96–184)                 | 130(92–185)                   | 130(92–179)                 | 138(90–177)             | 0.882   |
| Portal hypertension (%)                  | 21(27.6%)                   | 273(27.8%)                    | 112(27.2%)                  | 22(30.1%)               | 0.965   |
| Ishak score, median (IQR)               median (IQR) | 6(4–6) | 5(4–6) | 5(4–6) | 5(5–6) | 0.576 |
| Tumor size (cm), median (IQR)            | 6(3–8)                      | 5(4–8)                        | 5(4–8)                      | 6(4.5–9)                | 0.605   |
| Tumor Number                             | 0.377                       |                               |                             |                         |         |
| Solitary                                 | 64(84.2%)                   | 825(84%)                      | 356(86.4%)                  | 60(90.4%)               |         |
| Multiple                                 | 12(15.8%)                   | 157(16%)                      | 56(13.6%)                   | 7(9.6%)                 |         |

*P < 0.05 compared with the normal-weight BMI group. BMI: body mass index; HBsAg: hepatitis B surface antigen; HBeAg: hepatitis B e antigen; SD: standard deviation; ULN, upper limit of normal. ALT, alanine aminotransferase; AST, aspartate aminotransferase. ASA: American Society of Anesthesiologists category. IQR: interquartile range.

doi:10.1371/journal.pone.0099281.t001
**Discussion**

Surgeons are operating on obese patients in increasing numbers because the rate of obesity and overweight in adults has been rising all around the world in recent decades[4] and many types of cancers are related to obesity[6]. With co-morbidities and grade ≥III, ALT and blood loss(P<0.05) (Table 4). Logistic analysis indicated that BMI was not a risk factor for total complications.

---

**Table 2. Intraoperative Parameters of Patients who underwent Hepatectomy by Obesity Classification.**

| Intraoperative Parameters | Underweight (BMI<18.5) | Normal Weight (BMI:18.5–23.9) | Overweight (BMI:24.0–27.9) | Obesity (BMI≥28) | P value |
|---------------------------|-------------------------|--------------------------------|-----------------------------|-------------------|--------|
| (n = 76)                  | (n = 982)               | (n = 412)                      | (n = 73)                    |                   |        |
| Major resection (%)       | 30(39.5%)               | 359(36.6%)                    | 158(38.3%)                 | 27(37.0%)         | 0.902  |
| Extrahepatic procedures (%)| 12(15.8%)              | 199(20.3%)                    | 73(17.7%)                  | 20(27.4%)         | 0.196  |
| Hooking with ligation (%) | 25(32.9%)               | 339(34.5%)                    | 150(36.4%)                 | 24(32.9%)         | 0.864  |
| Inflow occlusion (%)      | 36(47.4%)               | 411(41.9%)                    | 163(39.6%)                 | 32(43.8%)         | 0.589  |
| Blood loss (mL) media(IQR) | 300(200–500)           | 400(200–600)                  | 400(200–600)               | 430(300–525)      | 0.224  |
| PRBCs transfusion (%)     | 16(21.1%)               | 177(18.0%)                    | 83(20.1%)                  | 12(16.4%)         | 0.709  |
| Plasma transfusion (%)    | 11(14.5%)               | 136(13.8%)                    | 70(17.0%)                  | 11(15.1%)         | 0.516  |
| Anatomic resection (%)    | 30(39.5%)               | 361(36.8%)                    | 145(35.2%)                 | 212(28.8%)        | 0.492  |

BMI: body mass index; SD: standard deviation; PRBCs: packed red blood cells.

**Table 3. Postoperative Outcomes of Patients who underwent Hepatectomy.**

| Postoperative Outcomes | Underweight (BMI<18.5) | Normal Weight (BMI:18.5–23.9) | Overweight (BMI:24.0–27.9) | Obesity (BMI≥28) | P value |
|------------------------|-------------------------|--------------------------------|-----------------------------|-------------------|--------|
| (n = 76)               | (n = 982)               | (n = 412)                      | (n = 73)                    |                   |        |
| Total complications    | 12*(15.8%)              | 288(29.3%)                     | 136(33.0%)                  | 28(38.4%)         | 0.008  |
| Major complications    | 3(3.9%)                 | 82(8.4%)                       | 31(7.5%)                    | 9(12.3%)          | 0.286  |
| Grade I                | 3(3.9%)                 | 94(9.6%)                       | 44(10.7%)                   | 5(6.8%)           | 0.261  |
| Grade II               | 6(7.9%)                 | 112(11.4%)                     | 61(14.8%)                   | 14(19.2%)         | 0.057  |
| Grade III              | 0(0%)                   | 49(5.0%)                       | 18(4.4%)                    | 4(5.5%)           | 0.054  |
| Grade IV               | 11(1.3%)                | 22(2.2%)                       | 6(1.5%)                     | 2(2.7%)           | 0.717  |
| 30-day Mortality       | 2(2.6%)                 | 11(1.1%)                       | 7(1.7%)                     | 3(4.1%)           | 0.293  |
| 90-day Mortality       | 2(2.6%)                 | 12(1.2%)                       | 8(1.9%)                     | 3(4.1%)           | 0.293  |
| Bile Leakage           | 0(0%)                   | 13(1.3%)                       | 8(1.9%)                     | 0(0%)             | 0.620  |
| Liver failure          | 6(7.9%)                 | 93(9.5%)                       | 50(12.1%)                   | 11(15.1%)         | 0.215  |
| Grade A                | 6(7.9%)                 | 32(3.3%)                       | 11(2.7%)                    | 1(1.4%)           | 0.008  |
| Grade B                | 2(2.6%)                 | 42(4.3%)                       | 31(7.5%)                    | 8(11%)            |        |
| Grade C                | 0(0%)                   | 19(1.9%)                       | 8(1.9%)                     | 2(2.7%)           |        |
| Ascites                | 1(1.3%)                 | 47(4.8%)                       | 19(4.6%)                    | 1(1.4%)           | 0.180  |
| Cardiovascular comp.   | 2(2.6%)                 | 80(8.8%)                       | 5(1.2%)                     | 1(1.4%)           | 0.568  |
| Pulmonary comp.        | 3(3.9%)                 | 61(6.2%)                       | 29(0.7%)                    | 6(8.2%)           | 0.664  |
| Infection comp.        | 2(2.6%)                 | 49(5.0%)                       | 26(6.1%)                    | 5(6.8%)           | 0.516  |
| Bleeding               | 1(1.3%)                 | 13(1.3%)                       | 4(1.0%)                     | 2(2.7%)           | 0.791  |
| Wound complication      | 1(1.3%)                 | 25(2.5%)                       | 26*(6.3%)                   | 8*(11.0%)         | <0.001 |
| Gastrointestinal comp. | 1(1.3%)                 | 19(1.9%)                       | 13(3.2%)                    | 4(5.5%)           | 0.221  |
| ICU stay requirement    | 16(21.1%)               | 274(27.9%)                     | 13(32.5%)                   | 23(31.5%)         | 0.132  |
| Hospital stay(days),median (IQR) | 12(10–15) | 12(10–15) | 12.5(10–15) | 12(10–14) | 0.382 |

P<0.05 compared with the normal-weight BMI group. BMI: body mass index; ICU: Intensive Care Unit; IQR: interquartile range.

doi:10.1371/journal.pone.0099281.t002
making clinical decisions. Liver resection on HCC patients with obesity and overweight when complications occurred in the overweight and obese patients. The accompanying chronic liver disease in HBV-related HCC patients may cause more severe complications than in other patients. Although many large-sample studies evaluating the safety of surgical outcomes due to associated co-morbidities. In our study, the overall complications and severity classified by the Clavien system were similar between the normal and BMI≥24 groups (overweight and obese patients), which did not agree with the assumed results. Several reasons can explain this unexpected outcome. First, patients with a relatively high BMI may have a higher nutritional and physiologic reserve than lower BMI patients and may thus withstand the various effects of hepatic resection. Second, the absence of unified standards in reported complications hampered proper evaluation of the surgery results in several large-sample studies. Third, for liver resection in HCC patients, most cohorts included only patients with cirrhosis. Our cohort included patients with HBV-related HCC. The accompanying chronic liver disease in HBV-related HCC patients may cause more severe complications than in other patients. We carried out a retrospective analysis of prospectively collected data on elective liver resection for HBV-related HCC patients. With a large sample of consecutive 1543 cases, our study would contribute to evaluating the risk for HCC patients with obesity and overweight when making clinical decisions.

It is well established that obese patients as well as overweight patients have more co-morbidities, such as cardiovascular disease and diabetes mellitus. In addition, two studies with large samples earlier indicated that obese and overweight patients did increase workload for surgeons by adding operating time or length of hospital stays. The findings from our study were consistent with some of the previous studies, not only in preoperative co-morbidities but also in postoperative outcomes. In general surgery, Dindo investigated a cohort of 6336 patients and found that obese patients had similar postoperative complications except for wound infection. Similarly, Haw et al. found that obesity did not increase the morbidity in a study including 1375 patients. For liver resection, Gedaly’s study included 1029 liver resections and showed that obese patients had similar postoperative complications than in other patients. Our result was three studies exclusively investigating obesity in HCC patients, which did not agree with the assumed results. Several reasons can explain this unexpected outcome. First, patients with a relatively high BMI may have a higher nutritional and physiologic reserve than lower BMI patients and may thus withstand the various effects of hepatic resection coupled with other therapies. Second, although obese and overweight patients had more co-morbidities, the patients were selected for safety before surgery in consideration of the morbidities, ASA score and liver function. However, more wound complications occurred in the overweight and obese patients. The reasons had been discussed by Dindo and Mullen. First, obese patients had excessive fat tissue, which has low regional
oxygen tension and relatively low blood perfusion, and may increase the chance for wound to infect. Second, obese patients have an underlying immune impairment[6]. And third, obese patients usually had larger incisions because of difficulty in exposure. Tension on the suture line might be more accentuated because of the bulky subcutaneous fat tissue[9].

However, a few potential limitations in our cohort should be considered. First, for BMI classification, we selected WGOC criteria, not the World Health Organization criteria, for BMI classification, and our results may not be generalizable to other countries or areas beyond China. Second, our results may not be generalizable to other patients beyond HCC patients. Third, patients were followed up for just a month and late complications such as incisional hernia can not be expected in our study.

In conclusion, we carried on a retrospective study with a large sample and found that overweight and obese patients with HBV-related HCC had more co-morbidities than did normal or underweight patients. However, overweight and obesity were not related with morbidity and mortality except for wound complication after liver resection. BMI is not a risk factor for complications after liver resection.

Author Contributions
Conceived and designed the experiments: HW Jiayin Yang XZ LY Jian Yang. Performed the experiments: HW LY Jian Yang. Analyzed the data: XZ Jian Yang. Contributed reagents/materials/analysis tools: Jian Yang. Wrote the paper: HW Jiayin Yang XZ LY Jian Yang.

References
1. Brux J, Sherman M, Practice Guidelines Committee AASLD (2005) Management of hepatocellular carcinoma. Hepatology 42: 1288–1296.
2. Hawn MT, Bian J, Leeth RR, Richie G, Allen N, et al. (2005) Impact of obesity on resource utilization for general surgical procedures. Ann Surg 241: 821–826; discussion 826–828.
3. Ogden CL, Yanovski SZ, Carroll MD, Flegal KM (2007) The epidemiology of obesity. Gastroenterology 132: 2087–2102.
4. Xi B, Liang Y, He T, Reilly KH, Hu Y, et al. (2012) Secular trends in the prevalence of general and abdominal obesity among Chinese adults, 1993–2009. Obes Rev 13: 287–296.
5. Chen CM (2008) Overview of obesity in Mainland China. Obes Rev 9 Suppl 1: 14–21.
6. Sun B, Karin M (2012) Obesity, inflammation, and liver cancer. J Hepatol 56: 704–713.
7. Vigano L, Kluger MD, Laurent A, Tayar C, Merle JC, et al. (2011) Liver resection in obese patients: results of a case-control study. HPB (Oxford) 13: 103–111.
8. Mullen JT, Davenport DL, Hutter MM, Hosokawa PW, Henderson WG, et al. (2008) Impact of body mass index on perioperative outcomes in patients undergoing major intra-abdominal cancer surgery. Ann Surg Oncol 15: 2164–2172.
9. Diindo M, Muller MK, Weber M, Clavien PA (2003) Obesity in general elective surgery. Lancet 361: 2032–2035.
10. Bower M, Wunderlich C, Brown R, Scoggins CR, McMasters KM, et al. (2012) Obese rather than neoadjuvant chemotherapy predicts steatohepatitis in surgery. Lancet 369: 14–21.
11. Saunders JK, Rosman AS, Neihaus D, Gouge TH, Melis M (2012) Safety of hepatectomy in noncirrhotic patients. Ann Surg 250: 1713–1721.
12. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, et al. (1995) Histological grading and staging of chronic hepatitis. J Hepatol 22: 696–699.
13. Okamura Y, Maeda A, Matsunaga K, Kanemoto H, Uesaka K (2012) Negative impact of low body mass index on surgical outcomes after hepatectomy for hepatocellular carcinoma. J Hepatobiliary Pancreat Sci 19: 449–457.
14. Cucchetti A, Cescon M, Ercolani G, Di Gioia P, Peri E, et al. (2011) Safety of hepatic resections in obese patients. Arch Surg 147: 331–337.
15. Itoh S, Ikeda Y, Kawanaka H, Okuyama T, Kawasaki K, et al. (2012) The effect of preoperative body mass index and outcomes in patients undergoing noncirrhotic hepatectomy. Ann Surg 256: 729–734.
16. Sun B, Karin M (2012) Obesity, inflammation, and liver cancer. J Hepatol 56: 14–21.
17. Wen T, Chen Z, Yan L, Li B, Zeng Y, et al. (2007) Continuous normothermic hepatic vascular inflow occlusion over 60 min for hepatectomy in patients with cirrhosis caused by hepatitis B virus. Hepatol Res 37: 346–352.
18. Pringle JH (1908) Notes on the Arrest of Hepatic Hemorrhage Due to Trauma. Ann Surg 48: 541–549.
19. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, et al. (2009) The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 230: 187–196.
20. Breitenstein S, De Oliveira ML, Raptis DA, Shankamanek K, Kambakampa P, et al. (2010) Novel and simple preoperative score predicting complications after liver resection in noncirrhotic patients. Ann Surg 252: 729–734.
21. Romano PS, Roos LL, Jollis JG (1995) Adjusting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 48: 1073–1079; discussion 1081–1090.
22. Charalambis ME, Pomper P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40: 373–383.
23. Rabbari NN, Garden OJ, Padbury R, Brooke-Smith M, Crawford M, et al. (2011) Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery 149: 713–724.
24. Ishak K, Bapista A, Blanchi L, Calla F, De Groote J, et al. (1995) Histological grading and staging of chronic hepatitis. J Hepatol 22: 696–699.
25. Mullen JT, Moorman DW, Davenport DL, (2009) The obesity paradox: body mass index and outcomes in patients undergoing nonbariatric general surgery. Ann Surg 250: 166–172.
26. Gedaly R, McHugh PP, Johnston TD, Jeon H, Ranjan D, et al. (2009) Obesity, diabetes, and smoking are important determinants of resource utilization in liver resection: a multicenter analysis of 1029 patients. Ann Surg 249: 414–419.
27. Mathur AK, Ghaferi AA, Osborne NH, Pawlik TM, Campbell DA, et al. (2010) Body mass index and adverse perioperative outcomes following hepatic resection. J Gastrointest Surg 14: 1293–1299.
28. Mathur AK, Ghaferi AA, Seil K, Sonnenday CJ, Englesbe MJ, et al. (2010) Influence of body mass index on complications and oncologic outcomes following hepatectomy for malignancy. J Gastrointest Surg 14: 499–510.
29. Balzan S, Nagrajaraj G, Fargas O, Gallicano Z, Dokmak S, et al. (2010) Safety of liver resections in obese and overweight patients. World J Surg 34: 2960–2968.
30. Bruix J, Castells A, Bosch J, Fru F, Faster J, et al. (1996) Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 111: 1018–1022.